Ling Wang , Aohan Li , ChenNing Zhang , Xudong Ding , Huili Xu
{"title":"舌下含服阿托品滴眼液治疗中风后溢泪：随机对照试验。","authors":"Ling Wang , Aohan Li , ChenNing Zhang , Xudong Ding , Huili Xu","doi":"10.1016/j.jstrokecerebrovasdis.2024.108050","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Sialorrhea is a common concern in patients with swallowing disorders after stroke. Atropine sulfate blocks the muscarinic receptors in the salivary glands and leads to reduced saliva production.</div></div><div><h3>Objective</h3><div>The present study aimed to assess the safety, efficacy, and tolerability of sublingual administration of atropine eye drops for treating sialorrhea after stroke.</div></div><div><h3>Design</h3><div>This was a prospective cohort study.</div></div><div><h3>Setting</h3><div>This study was conducted at Xiangyang No. 1 People's Hospital, Hubei University of Medicine, Hubei Province, China.</div></div><div><h3>Population</h3><div>Stroke patients with sialorrhea were analyzed.</div></div><div><h3>Methods</h3><div>One hundred stroke patients with sialorrhea were randomly assigned to the control group and the test group (<em>n</em> = 50 per group). The control group received routine swallowing rehabilitation training and neuromuscular electrical stimulation. The test group received therapy with 1% atropine eye drops, wherein one drop was administered sublingually 3 times per day. The Sialorrhea Scoring Scale and the incidence of adverse events were used to compare the severity of sialorrhea in the two groups.</div></div><div><h3>Results</h3><div>The mean (standard deviation) sialorrhea score improved from 5.12 for the control group with routine rehabilitation training to 3.94 for the test group with atropine eye drop administration (<em>P</em> < 0.01). No significant differences in the incidence of adverse events were observed between the two groups.</div></div><div><h3>Conclusions</h3><div>The sublingual administration of 1% atropine eye drops three times per day can reduce the degree of sialorrhea to an extent more than that achieved with routine rehabilitation training; thus, this approach is effective, safe, and minimally invasive for treating sialorrhea after stroke.</div></div>","PeriodicalId":54368,"journal":{"name":"Journal of Stroke & Cerebrovascular Diseases","volume":"33 12","pages":"Article 108050"},"PeriodicalIF":2.0000,"publicationDate":"2024-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Sublingual administration of atropine eye drops for treating sialorrhea after stroke: A randomized controlled trial\",\"authors\":\"Ling Wang , Aohan Li , ChenNing Zhang , Xudong Ding , Huili Xu\",\"doi\":\"10.1016/j.jstrokecerebrovasdis.2024.108050\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>Sialorrhea is a common concern in patients with swallowing disorders after stroke. Atropine sulfate blocks the muscarinic receptors in the salivary glands and leads to reduced saliva production.</div></div><div><h3>Objective</h3><div>The present study aimed to assess the safety, efficacy, and tolerability of sublingual administration of atropine eye drops for treating sialorrhea after stroke.</div></div><div><h3>Design</h3><div>This was a prospective cohort study.</div></div><div><h3>Setting</h3><div>This study was conducted at Xiangyang No. 1 People's Hospital, Hubei University of Medicine, Hubei Province, China.</div></div><div><h3>Population</h3><div>Stroke patients with sialorrhea were analyzed.</div></div><div><h3>Methods</h3><div>One hundred stroke patients with sialorrhea were randomly assigned to the control group and the test group (<em>n</em> = 50 per group). The control group received routine swallowing rehabilitation training and neuromuscular electrical stimulation. The test group received therapy with 1% atropine eye drops, wherein one drop was administered sublingually 3 times per day. The Sialorrhea Scoring Scale and the incidence of adverse events were used to compare the severity of sialorrhea in the two groups.</div></div><div><h3>Results</h3><div>The mean (standard deviation) sialorrhea score improved from 5.12 for the control group with routine rehabilitation training to 3.94 for the test group with atropine eye drop administration (<em>P</em> < 0.01). No significant differences in the incidence of adverse events were observed between the two groups.</div></div><div><h3>Conclusions</h3><div>The sublingual administration of 1% atropine eye drops three times per day can reduce the degree of sialorrhea to an extent more than that achieved with routine rehabilitation training; thus, this approach is effective, safe, and minimally invasive for treating sialorrhea after stroke.</div></div>\",\"PeriodicalId\":54368,\"journal\":{\"name\":\"Journal of Stroke & Cerebrovascular Diseases\",\"volume\":\"33 12\",\"pages\":\"Article 108050\"},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2024-10-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Stroke & Cerebrovascular Diseases\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1052305724004944\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"NEUROSCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Stroke & Cerebrovascular Diseases","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1052305724004944","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
Sublingual administration of atropine eye drops for treating sialorrhea after stroke: A randomized controlled trial
Background
Sialorrhea is a common concern in patients with swallowing disorders after stroke. Atropine sulfate blocks the muscarinic receptors in the salivary glands and leads to reduced saliva production.
Objective
The present study aimed to assess the safety, efficacy, and tolerability of sublingual administration of atropine eye drops for treating sialorrhea after stroke.
Design
This was a prospective cohort study.
Setting
This study was conducted at Xiangyang No. 1 People's Hospital, Hubei University of Medicine, Hubei Province, China.
Population
Stroke patients with sialorrhea were analyzed.
Methods
One hundred stroke patients with sialorrhea were randomly assigned to the control group and the test group (n = 50 per group). The control group received routine swallowing rehabilitation training and neuromuscular electrical stimulation. The test group received therapy with 1% atropine eye drops, wherein one drop was administered sublingually 3 times per day. The Sialorrhea Scoring Scale and the incidence of adverse events were used to compare the severity of sialorrhea in the two groups.
Results
The mean (standard deviation) sialorrhea score improved from 5.12 for the control group with routine rehabilitation training to 3.94 for the test group with atropine eye drop administration (P < 0.01). No significant differences in the incidence of adverse events were observed between the two groups.
Conclusions
The sublingual administration of 1% atropine eye drops three times per day can reduce the degree of sialorrhea to an extent more than that achieved with routine rehabilitation training; thus, this approach is effective, safe, and minimally invasive for treating sialorrhea after stroke.
期刊介绍：
The Journal of Stroke & Cerebrovascular Diseases publishes original papers on basic and clinical science related to the fields of stroke and cerebrovascular diseases. The Journal also features review articles, controversies, methods and technical notes, selected case reports and other original articles of special nature. Its editorial mission is to focus on prevention and repair of cerebrovascular disease. Clinical papers emphasize medical and surgical aspects of stroke, clinical trials and design, epidemiology, stroke care delivery systems and outcomes, imaging sciences and rehabilitation of stroke. The Journal will be of special interest to specialists involved in caring for patients with cerebrovascular disease, including neurologists, neurosurgeons and cardiologists.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
